A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results
BGB-A445 was well tolerated and demonstrated on-target immune activation at clinically relevant doses. Antitumor activity was observed across cohorts.
Authors
- Mark Voskoboynik (ORCID: https://orcid.org/0000-0002-4242-1300)
- Diwakar Davar (ORCID: https://orcid.org/0000-0002-7846-8055)
- Kenneth J. O’Byrne (ORCID: https://orcid.org/0000-0002-6754-5633)
- Hugh Giovinazzo
- Yan Dong (ORCID: https://orcid.org/0000-0003-0016-9028)
- Daphne Day (ORCID: https://orcid.org/0000-0001-8262-2441)
- Bo Gao (ORCID: https://orcid.org/0000-0002-7881-6603)
- Tarek Meniawy (ORCID: https://orcid.org/0000-0002-1457-6137)
- Sanjeev Deva (ORCID: https://orcid.org/0000-0002-7933-303X)
- Jayesh Desai (ORCID: https://orcid.org/0000-0003-4246-9344)
- Kunyu Yang (ORCID: https://orcid.org/0000-0002-2575-4736)
- Meili Sun (ORCID: https://orcid.org/0000-0002-4914-6508)
- Xin Chen (ORCID: https://orcid.org/0000-0001-6212-2335)
- Tianshu Liu (ORCID: https://orcid.org/0000-0002-2318-2869)
- Xinmin Yu
- Tahmina Rahman
- Xiaofei Qu (ORCID: https://orcid.org/0000-0002-2855-6970)
- Shiangjiin Leaw
- Marco Matos
Institutions
- Union Hospital (HK)
- Australian Research Council (AU)
- The University of Western Australia (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Fudan University (CN)
- Peter MacCallum Cancer Centre (AU)
- Auckland City Hospital (NZ)
- Breast Cancer Network Australia (AU)
- Princess Alexandra Hospital (AU)
- Blacktown & Mount Druitt Hospital (AU)
- Council of Australasian University Librarians (AU)
- Zhejiang Cancer Hospital (CN)
- Samsung (United States) (US)
- Jinan Central Hospital (CN)
- Flinders Private Hospital (AU)
- Shandong Provincial Hospital (CN)
- Monash Health (AU)
- Zhongshan Hospital (CN)
- UPMC Hillman Cancer Center (US)
- Cambridge Collaborative (United States) (US)
- Danone (China) (CN)
- Universidad San Carlos (PY)
- Linear Clinical Research (AU)
- Shandong First Medical University (CN)
- Medical Oncology Group of Australia (AU)
- Huazhong University of Science and Technology (CN)
- Monash University (AU)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s00280-025-04809-1
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05